Stretta Procedure for GERD: Successful 10 Year Follow-Up Data Presented at Digestive Disease Week--Sustained Improvement, Long-Term Efficacy
5/19/2013
| ORLANDO, Fla. , May 19, 2013 The non-surgical Stretta® procedure employing low power and low temperature radiofrequency (RF) energy is effective in control of gastroesophageal reflux disease (GERD), and eliminates or reduces the need for medication 10 years post-procedure, according to an independent, prospective long-term assessment presented today at the Digestiv... [Comments] |
New Study Shows Full Spectrum Endoscopy Procedure Reduces The 'Miss Rate' of Adenomas During Colonoscopy
5/18/2013
| ORLANDO, Fla. , May 18, 2013 Although colonoscopy exams prevent many colon cancer deaths 1 and are considered the most sensitive method for detecting colorectal cancers 2 , the procedure is not completely effective in preventing cancer cases 3 . EndoChoice ® Inc. today unveiled research that shows that its new Fuse™ system significantly improves the accuracy of th... [Comments] |
New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses
5/18/2013
| SAN FRANCISCO , May 18, 2013 The Open Paradigm Project, in collaboration with MadinAmerica.com , Occupy Psychiatry , and leading organizations in the movement to reform mental health care, announces a social media campaign showcasing video testimonials by individuals negatively impacted by the traditional psychiatric model, which focuses on pathology and illness... [Comments] |
Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm
5/18/2013
| NEW YORK , May 18, 2013 Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at AVEO Pharmaceuticals, Inc. ("AVEO" or the "Company") (NASDAQ: AVEO). (Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO ) The investigation focuses on whether the Company and its executives violated federal securities laws by... [Comments] |
Wild Medicine On View at The New York Botanical Garden Through Sept. 8
5/17/2013
| NEW YORK , May 17, 2013 The power of plants to cure and rejuvenate, one of the most important ways in which mankind depends on the plant kingdom, is the subject of The New York Botanical Garden's multifaceted exhibition Wild Medicine: Healing Plants Around the World, Featuring The Italian Renaissance Garden, on view from May 18 through September 8, 2013. (Photo: ... [Comments] |
Statistical Challenges in Medical Device Trail Evaluation
5/17/2013
| SHANGHAI , May 17, 2013 Medical devices are any medical items that are neither a drug nor a biological product. In light of their different mechanisms, actions and regulatory requirements, medical device (MD) trail evaluations are much more complicated than drug trails due to their unique clinical practices. Currently, the EMEA only evaluates MD safety instead of evaluating bo... [Comments] |
Lakeland Industries to Report Fiscal Fourth Quarter and Year End Financial Results and Conduct Conference Call
5/17/2013
| RONKONKOMA, N.Y. , May 17, 2013 Lakeland Industries, Inc. (NASDAQ: LAKE ), a leading global manufacturer of protective clothing for industry, healthcare and to first responders on the federal, state and local levels, will release its financial results for the fiscal 2013 fourth quarter and year ended January 31, 2013, on Tuesday, May 21, 2013 at stock market close and w... [Comments] |
Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
5/17/2013
| SAN DIEGO , May 17, 2013 Sorrento Therapeutics, Inc. (OTCBB: SRNE; or STI) announced today that its Fast-Track Advanced Technology Small Business Technology Transfer Research (STTR) grant (#1R42AI098182-02) from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), supporting the development of novel huma... [Comments] |
Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
5/17/2013
| SAN DIEGO , May 17, 2013 Orexigen® Therapeutics, Inc. (Nasdaq: OREX ) today announced that management will present a company overview at the UBS Global Healthcare Conference in New York . The presentation is scheduled for Wednesday, May 22 nd at 11 a.m. Eastern Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relati... [Comments] |
Internal Communication Strategies and Tactics that Resonate with Key Stakeholders and Drive Organizational Effectiveness
5/17/2013
| CHAPEL HILL, N.C. , May 17, 2013 Technology advances have had a profound effect on how organizations communicate internally. Faced with a constantly evolving communication environment, companies need to continuously adjust their strategies and tactics for communicating with internal executives. It is challenging, however, to gauge the effectiveness of all the strategies,... [Comments] |